Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$CPXX Headline CPXX NCI/Stanford Ph2 AML trial just suspended pending IRB review
Thanks, you as well.
Wrinks I have to agree with you 100%.
This is what's causing it.
http://bit.ly/1Vnys5W
Story is from just another short spreading misinformation. Black Box warning is not really an issue with Veltassa.
Read this article also. http://bit.ly/1TGlsap
True, sometimes he does.
$heff has not sold his $TPIV, he posts it when he sells. Always hear some people complaining about this stock going down, they're usually the ones selling. So who else do you want to blame this decline on?
from Sheff's board.
$TPIV..$.715..Looks like we get news next week. Should be a fun filled week with "much anticipated" news.
https://investorshub.advfn.com/secure/priv.aspx?r=http%3a%2f%2finvestorshub.advfn.com%2fuimage%2fuploads%2f2016%2f4%2f1%2fqlksnimage.jpg
$DEPO court rules in favor of Depomed. IPR Appeal affirmed http://1.usa.gov/1pAdinB
$DEPO court rules in favor of Depomed. IPR Appeal affirmed http://1.usa.gov/1pAdinB
He also states in this interview that P2 would take about 2 years. That would put results at about Sept 2016. So being critical of Glynn IS NOT warranted.
yeah I saw.
$PETX Yes, waiting for it to move on the news.
$PETX FDA Approves Galliprant, a New Animal Drug for Osteoarthritis in Dogs
http://www.fda.gov/AnimalVeterinary/NewsEvents/CVMUpdates/ucm491552.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery
$PIRS printing $2s
Do you have links for your posts, including insiders dumping!?
Gotta' stink bid in @ .81
What is their price target now that $EBIO data failed and they don't see a way forward for this drug?“We are disappointed that isunakinra failed to meet its primary endpoint, and based on these overall results we see no immediate path forward in allergic conjunctivitis,” said Abbie Celniker, PhD, President and CEO of Eleven Biotherapeutics."
$EBIO Yes, I'm watching it.
$EBIO Yeah just saw that. Glad I didn't own any before news.
$EBIO may not resume trading at its closing price.
Have you looked at the indices yet? That's why all the selling.
Citrati that is quite an interesting story. It sounds exactly like something the power brokers of the world would do . This world may be going to hell in a bucket and I'm not enjoying the ride.
I have it on watch list. Thx.
Good luck with it.
$SRPT not in it.
Thanks tom. We seem to be on the same page about these antics.
Yes I pay attention to his picks but you have to be careful or you could get burned. His latest picks are $QURE and $TNXP. While his minions are pumping they're dumping.
Tom, excellent post. You hit the nail right on the head. Always knew this to be true about that crew. I'll save your post. I hope others can figure it out also.
Same to you Blu. Appreciate your posts.
np. At 65 I still have to vent now and then.
Yes he is. But the fact that he didn't this time is fine with me.
I agree with you.
Go to his board and read posts 92041 and 92042.
That's my point. He does not control the market, though some people seem to think he does.
$heff has reduced his position in $TPIV.
From $heff: $TPIV..The FDA has granted an orphan drug designation to TPIV 200 as a treatment for patients with ovarian cancer http://ow.ly/VUfy0 (OncLive)
The FDA has granted an orphan drug designation to the multi-epitope folate receptor alpha (FRa) vaccine TPIV 200 as a treatment for patients with ovarian cancer, according to a statement from the drug's developer, TapImmune.The orphan designation for TPIV 200 was based on findings from a phase I study, which were electronically published in conjunction with the 2015 ASCO Annual Meeting. In the study, treatment with the vaccine was associated with FRa-specific T-cell response that persisted beyond the completion of the study for a majority of patients. In total, FRa is expressed on nearly 90% of ovarian cancer cells. - See more at: http://www.onclive.com/web-exclusives/multi-epitope-vaccine-granted-orphan-designation-for-ovarian-cancer#sthash.07wzMG16.dpuf
That's true. There's another roaming these boards who is much worse.
I'm not allowed on his board because I called him a front runner.